基于6-CH 3环戊二烯[ d ]嘧啶支架和吡咯并[2,3- d ]嘧啶支架设计并合成了两类分子。吡咯并[2,3- d ]嘧啶是通过2-氰基-4,4-二乙氧基丁酸乙酯和乙脒反应合成的,乙脒又被氯化并与适当的苯胺反应得到1和2。由3-甲基己二酸得到环戊二烯[ d ]嘧啶,然后与乙脒反应得到环戊二烯[ d ]嘧啶支架。氯化并与适当的苯胺反应得到 (±)- 3 ·HCl-(±)- 7·盐酸。化合物1和(±) -3 ·HCl在纳摩尔范围内具有有效的抗增殖活性。化合物 (±)- 3 ·HCl 的效力明显高于1。机理研究表明,1和(±)- 3 ·HCl引起细胞微管丢失,抑制纯化微管蛋白的聚合,抑制秋水仙碱的结合。建模研究显示这些化合物在秋水仙碱位点内的相互作用。这些新抑制剂的鉴定也可以克服临床相关的耐药机制,为秋水仙碱位点药物提供了新的支架。
4-anilino- and 4-(alkylamino)-2-methylpyrrolo[2,3-d]pyrimidines showed cytokinin and anticytokininactivities, depending on the structure of their 4-substituents, and the antagonistic nature of the latter was established kinetically. The effect of the substituent on these activities was analyzed quantitatively by using physicochemical parameters and regression analysis to give a single, common equation for
[EN] PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIMIDINE ET COMPOSÉS DE PYRIMIDO INDOLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
申请人:UNIV HOLY GHOST DUQUESNE
公开号:WO2016022890A1
公开(公告)日:2016-02-11
The present invention discloses substituted pyrimidine and pyrimido indole compounds and optionally pharmaceutically acceptable salts, hydrates or solvates thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE
申请人:Duquesne University of the Holy Spirit
公开号:US20170253612A1
公开(公告)日:2017-09-07
The present invention discloses a compound comprising the formula:
wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH
2
, and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
US9688690B2
申请人:——
公开号:US9688690B2
公开(公告)日:2017-06-27
Synthesis and Discovery of Water-Soluble Microtubule Targeting Agents that Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance
作者:Aleem Gangjee、Ying Zhao、Lu Lin、Sudhir Raghavan、Elizabeth G. Roberts、April L. Risinger、Ernest Hamel、Susan L. Mooberry
DOI:10.1021/jm101010n
日期:2010.11.25
Two classes of molecules were designed and synthesized based on a 6-CH3 cyclopenta[d]pyrimidine scaffold and a pyrrolo[2,3-d]pyrimidine scaffold. The pyrrolo[2,3-d]pyrimidines were synthesized by reacting ethyl 2-cyano-4,4-diethoxybutanoate and acetamidine, which in turn was chlorinated and reacted with the appropriate anilines to afford 1 and 2. The cyclopenta[d]pyrimidines were obtained from 3-methyladapic
基于6-CH 3环戊二烯[ d ]嘧啶支架和吡咯并[2,3- d ]嘧啶支架设计并合成了两类分子。吡咯并[2,3- d ]嘧啶是通过2-氰基-4,4-二乙氧基丁酸乙酯和乙脒反应合成的,乙脒又被氯化并与适当的苯胺反应得到1和2。由3-甲基己二酸得到环戊二烯[ d ]嘧啶,然后与乙脒反应得到环戊二烯[ d ]嘧啶支架。氯化并与适当的苯胺反应得到 (±)- 3 ·HCl-(±)- 7·盐酸。化合物1和(±) -3 ·HCl在纳摩尔范围内具有有效的抗增殖活性。化合物 (±)- 3 ·HCl 的效力明显高于1。机理研究表明,1和(±)- 3 ·HCl引起细胞微管丢失,抑制纯化微管蛋白的聚合,抑制秋水仙碱的结合。建模研究显示这些化合物在秋水仙碱位点内的相互作用。这些新抑制剂的鉴定也可以克服临床相关的耐药机制,为秋水仙碱位点药物提供了新的支架。